Published in Hum Genomics Proteomics on August 03, 2010
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
Wnt signaling: a common theme in animal development. Genes Dev (1997) 12.94
Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med (2003) 12.94
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell (2003) 12.50
A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A (1996) 11.37
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet (2008) 10.49
Subgenual prefrontal cortex abnormalities in mood disorders. Nature (1997) 9.36
Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry (2007) 8.11
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6.88
Whole-genome association study of bipolar disorder. Mol Psychiatry (2008) 6.80
A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry (2007) 6.72
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry (1999) 5.63
Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A (1996) 5.24
The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr (1996) 4.62
Neural and developmental actions of lithium: a unifying hypothesis. Cell (1989) 4.13
Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry (2002) 3.78
Lithium salts in the treatment of psychotic excitement. Med J Aust (1949) 3.73
Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet (2010) 3.72
Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry (2009) 3.64
Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci U S A (2009) 3.49
Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet (2003) 3.08
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry (2008) 3.01
The anatomy of mood disorders--review of structural neuroimaging studies. Biol Psychiatry (1997) 2.86
Priorities and standards in pharmacogenetic research. Nat Genet (2005) 2.65
Functional gene screening in embryonic stem cells implicates Wnt antagonism in neural differentiation. Nat Biotechnol (2002) 2.64
pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response. J Cell Biol (2006) 2.62
A common mechanism of action for three mood-stabilizing drugs. Nature (2002) 2.58
A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry (1998) 2.56
The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord (1998) 2.47
Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet (2010) 2.46
What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry (2004) 2.43
Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry (2001) 2.32
Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth. Neuron (2006) 2.23
A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics (2007) 2.13
Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem (1997) 2.12
A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res (1998) 2.12
Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun (2001) 2.08
Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci U S A (2003) 2.06
Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder. Mol Psychiatry (2008) 1.92
The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry (2007) 1.88
A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry (2009) 1.84
Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol (2005) 1.81
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem (1999) 1.77
Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23. Nat Genet (1996) 1.76
In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology (2004) 1.73
Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol (2005) 1.73
The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem (2001) 1.73
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) (2001) 1.60
Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord (2009) 1.57
Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Arch Gen Psychiatry (1995) 1.55
An economic evaluation of manic-depressive illness--1991. Soc Psychiatry Psychiatr Epidemiol (1995) 1.53
Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol (2000) 1.52
Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord (2002) 1.50
microRNA regulation of synaptic plasticity. Neuromolecular Med (2009) 1.49
Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci U S A (1995) 1.47
Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry (2000) 1.46
Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat Genet (2003) 1.46
Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions. Biol Psychiatry (1998) 1.44
Is response to prophylactic lithium a familial trait? J Clin Psychiatry (2002) 1.43
Suicide in bipolar disorder: Risks and management. CNS Spectr (2006) 1.43
Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry (2000) 1.38
From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev (2008) 1.35
Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology (2002) 1.34
A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry (2009) 1.33
Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry (1999) 1.30
Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans (2009) 1.27
Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res (1997) 1.24
Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther (2002) 1.23
Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord (2007) 1.20
Double-blind and open prospective studies on lithium prophylaxis in affective disorders. Psychiatr Neurol Neurochir (1974) 1.18
Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry (2007) 1.17
Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry (2001) 1.16
Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem (1996) 1.15
Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord (2005) 1.14
Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions. Neurosci Res (2009) 1.14
Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate (2007) 1.14
Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet (2004) 1.11
Lithium response and genetics of affective disorders. J Affect Disord (1994) 1.11
Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord (2007) 1.09
Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet (1999) 1.09
The phenotypic spectra of bipolar disorder. Eur Neuropsychopharmacol (2004) 1.09
The effects of lithium on myo-inositol levels in layers of frontal cerebral cortex, in cerebellum, and in corpus callosum of the rat. J Neurochem (1980) 1.07
The phenotypes of bipolar disorder: relevance for genetic investigations. Mol Psychiatry (2005) 1.06
Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry (1999) 1.05
Family, twin, and adoption studies of bipolar disease. Curr Psychiatry Rep (2002) 1.05
Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett (2004) 1.04
Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells. Neuroscience (2007) 1.04
Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry (1998) 1.02
Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry (1974) 1.02
Essential role of the LIM domain in the formation of the PKCepsilon-ENH-N-type Ca2+ channel complex. Cell Signal (2005) 1.01
Findings from bipolar disorder genome-wide association studies replicate in a Finnish bipolar family-cohort. Mol Psychiatry (2009) 1.01
Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet (2008) 1.01
Impact of bipolar disorder in employed populations. Am J Manag Care (2008) 1.00
MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol (2009) 0.99
Topiramate increases cerebral GABA in healthy humans. Neurology (1998) 0.99
Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord (2005) 0.98
COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study. Schizophr Res (2005) 2.12
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics (2010) 1.09
Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Med (2013) 1.01
Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging (2011) 1.00
The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology (2010) 0.98
Migraine and tumour necrosis factor gene polymorphism. An association study in a Sardinian sample. J Neurol (2009) 0.97
Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics (2011) 0.96
Age at onset in Sardinian bipolar I patients: evidence for three subgroups. Bipolar Disord (2008) 0.94
Interacting genes in lithium prophylaxis: preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients. Neurosci Lett (2009) 0.94
Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology (2005) 0.93
Admixture analysis of age at onset in bipolar disorder. Psychiatry Res (2010) 0.87
Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacol Res (2013) 0.86
A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet (2005) 0.86
The brain-derived neurotrophic factor gene in suicidal behaviour: a meta-analysis. Int J Neuropsychopharmacol (2011) 0.86
Pharmacogenomics of bipolar disorder. Pharmacogenomics (2013) 0.85
Alzheimer's disease: case-control association study of polymorphisms in ACHE, CHAT, and BCHE genes in a Sardinian sample. Am J Med Genet B Neuropsychiatr Genet (2007) 0.85
Association study in a Sardinian sample between bipolar disorder and the nuclear receptor REV-ERBalpha gene, a critical component of the circadian clock system. Bipolar Disord (2009) 0.85
Renal function during long-term lithium treatment: a cross-sectional and longitudinal study. BMC Med (2015) 0.83
The PDLIM5 gene and lithium prophylaxis: an association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacol Res (2008) 0.82
Impact of sunlight on the age of onset of bipolar disorder. Bipolar Disord (2012) 0.82
Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients. J Mol Neurosci (2015) 0.81
Long-term lithium treatment and survival from external causes including suicide. J Clin Psychopharmacol (2007) 0.81
Differential effect of lithium on spermidine/spermine N1-acetyltransferase expression in suicidal behaviour. Int J Neuropsychopharmacol (2013) 0.80
Age at onset in Canadian schizophrenia patients: admixture analysis. Schizophr Res (2009) 0.80
A case-control association study of the PDLIM5 gene and bipolar disorder in a Sardinian sample. Psychiatr Genet (2008) 0.80
NRG1 and BDNF genes in schizophrenia: an association study in an Italian case-control sample. Psychiatry Res (2010) 0.79
Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain (2007) 0.79
Adverse drug reactions: role of pharmacogenomics. Pharmacol Res (2004) 0.79
No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. Psychiatry Res (2009) 0.79
Mixture analysis of age at onset in migraine without aura: evidence for three subgroups. Headache (2010) 0.78
Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.77
Prognostic models in bipolar disorder: can the prediction of the long-term clinical course rely on the integration of clinical and molecular data? Biomark Med (2014) 0.77
Continuation versus discontinuation of lithium during pregnancy: a retrospective case series. J Clin Psychopharmacol (2014) 0.77
Association study between the phenotype migraine without aura-panic disorder and dopaminergic receptor genes. Pharmacol Res (2003) 0.77
C9ORF72 repeat expansion and bipolar disorder - is there a link? No mutation detected in a Sardinian cohort of patients with bipolar disorder. Bipolar Disord (2014) 0.77
Preliminary Transcriptome Analysis in Lymphoblasts from Cluster Headache and Bipolar Disorder Patients Implicates Dysregulation of Circadian and Serotonergic Genes. J Mol Neurosci (2015) 0.77
Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother (2004) 0.77
[Evaluation of lithium treatment response in Sardinian bipolar patients]. Riv Psichiatr (2010) 0.77
Association study of GABRG2 polymorphisms with suicidal behaviour in schizophrenia patients with alcohol use disorder. Neuropsychobiology (2014) 0.76
Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-α gene (PPARA) and schizophrenia. Eur Neuropsychopharmacol (2012) 0.76
Investigation of the genetic interaction between BDNF and DRD3 genes in suicidical behaviour in psychiatric disorders. World J Biol Psychiatry (2014) 0.75
Manic-depressive illness: an association study with the inositol polyphosphate 1-phosphatase and serotonin transporter genes. Psychiatr Genet (2002) 0.75
Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS One (2017) 0.75
Are serotonin 3A and 3B receptor genes associated with suicidal behavior in schizophrenia subjects? Neurosci Lett (2010) 0.75
Evaluation of lithium response in episodic cluster headache: a retrospective case series. Headache (2012) 0.75
No association of endocannabinoid genes with bipolar disorder or lithium response in a Sardinian sample. Psychiatry Res (2013) 0.75
Genetic risk of suicidal behavior in bipolar spectrum disorder: analysis of 737 pedigrees. Bipolar Disord (2013) 0.75
A retrospective case series of bipolar patients with adjunctive carbamazepine in long-term lithium treatment: evaluation of the effectiveness. J Clin Psychopharmacol (2011) 0.75